Quantitative iTRAQ-based proteomic identification of candidate biomarkers for diabetic nephropathy in plasma of type 1 diabetic patients

Clinical Proteomics

Volumn 6, Issue 4, 2010, Pages 105-114

  Overgaard, Anne Julie ^a   Thingholm, Tine E ^b   Larsen, Martin R ^b   Tarnow, Lise ^c   Rossing, Peter ^c   McGuire, James N ^a   Pociot, Flemming ^a,d  

^a HAGEDORN RESEARCH INSTITUTE   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c STENO DIABETES CENTER   (Denmark)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Diabetic nephropathy; iTRAQ; Multiplex immunoassay technology; Pathway analysis; Protein networks; Quantitative proteomics

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CLUSTERIN; HEXAPEPTIDE; PROTEIN; PROTEOME;

ADULT; ANALYTIC METHOD; ARTICLE; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; FEMALE; HUMAN; IMMUNOASSAY; INSULIN DEPENDENT DIABETES MELLITUS; ISOBARIC MASS TAG; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; ONLINE SYSTEM; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY;

EID: 78649690330     PISSN: 15426416     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12014-010-9053-0     Document Type: Article

References (34)

1. Finne P, Reunanen A, Stenman S, Groop P-H, Gronhagen-Riska C. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA. 2005;294:1782-87.
2. Daneman D. Type 1 diabetes. Lancet. 2006;367:847-58.
3. Cameron JS. The discovery of diabetic nephropathy: from small print to centre stage. J Nephrol. 2006;19:75-87.
4. Kilpatrick ES, Rigby AS, Atkin SL. HbA1c variability and the risk of microvascular complications in type 1 diabetes: data from the DCCT. Diabetes Care. 2008;31:2198-202.
5. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Brit Med J. 1982;285:685-88.
6. Ahmad J. Renin-angiotensin system blockade in diabetic nephropathy. Diab Metab Synd: Clin Res Rev. 2008;2:135-58.
7. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, and The Collaborative Study, G. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-62.
8. Overgaard A, Hansen H, Lajer M, Pedersen L, Tarnow L, Rossing P, et al. Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy. Proteome Science. 2010;8:4.
9. Boschetti E, Righetti PG. The ProteoMiner in the proteomic arena: a non-depleting tool for discovering low-abundance species. J Proteomics. 2008;71:255-64.
10. Lam KS, Lebl M, Krchnak V. The 'one-bead-one-compound' combinatorial library method. Chem Rev. 1997;97:411-48.
11. Furka Á, Sebestyén F, Asgedom M, Dibó G. General method for rapid synthesis of multicomponent peptide mixtures. Int J Pept Protein Res. 1991;37:487-93.
12. Righetti PG, Boschetti E, Lomas L, Citterio A. Protein equalizer technology: the quest for a democratic proteome. Proteomics. 2006;6:3980-92.
13. Righetti PG, Castagna A, Antonioli P, Boschetti E. Prefractionation techniques in proteome analysis: the mining tools of the third millennium. Electrophoresis. 2005;26:297-319.
14. Rossing K, Mischak H, Dakna M, Zurbig P, Novak J, Julian BA, et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol. 2008;19:1283-90.
15. Nielsen SE, Sugaya T, Tarnow L, Lajer M, Schjoedt KJ, Astrup AS, et al. Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care. 2009;32:1684-88.
16. Rewitz KF, Larsen MR, Lobner-Olesen A, Rybczynski R, O'Connor MB, Gilbert LI. A phosphoproteomics approach to elucidate neuropeptide signal transduction controlling insect metamorphosis. Insect Biochem Mol Biol. 2009;39:475-83.
17. Hoorn EJ, Hoffert JD, Knepper MA. Combined proteomics and pathways analysis of collecting duct reveals a protein regulatory network activated in vasopressin escape. J Am Soc Nephrol. 2005;16:2852-63.
18. Apakkan Aksun S, Özmen D, Özmen B, Parildar Z, Mutaf I, Turgan N, et al. β2-Microglobulin and cystatin C in type 2 diabetes: assessment of diabetic nephropathy. Exp Clin Endocrinol Diabetes. 2003;112:195-200.
19. Gu W, Zou LX, Shan PF, Chen YD. Analysis of urinary proteomic patterns for diabetic nephropathy by ProteinChip. Proteom Clin APPL. 2008;2:744-50.
20. Hong CY, Chia KS. Markers of diabetic nephropathy. J Diabetes its Complicat. 1998;12:43-60.
21. Hyun-Jung K, Hyun-Syuk Y, Chan-Wha K. Proteomics in diabetic nephropathy. Proteom Clin APPL. 2008;2:301-11.
22. Ralhan R, DeSouza LV, Matta A, Chandra Tripathi S, Ghanny S, Datta Gupta S, et al. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics. 2008;7:1162-73.
23. Keshamouni VG, Michailidis G, Grasso CS, Anthwal S, Strahler JR, WalkerA, et al. Differential protein expression profiling by iTRAQ-2dlc-ms/ms of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res. 2006;5:1143-54.
24. Pernemalm M, Orre LM, Lengqvist J, Wikstrom P, Lewensohn R, Lehtio J. Evaluation of three principally different intact protein prefractionation methods for plasma biomarker discovery. J Proteome Res. 2008;7:2712-22.
25. Thingholm T, Palmisano G, Kjeldsen F, Larsen MR. Undesirable charge-enhancement of isobaric tagged phosphopeptides leads to reduced identification efficiency. J Proteome Res. 2010;9:4045-52.
26. Rutledge JC, Ng KF, Aung HH, Wilson DW. Role of triglyceride-rich lipoproteins in diabetic nephropathy. Nat Rev Nephrol. 2010;6:361-70.
27. Hirano T, Sakaue T, Misaki A, Murayama S, Takahashi T, Okada K, et al. Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII. Kidney Int. 2003;63:2171-77.
28. Onuma T, Laffel LM, Angelico MC, Krolewski AS. Apolipoprotein E genotypes and risk of diabetic nephropathy. J Am Soc Nephrol. 1996;7:1075-78.
29. Araki S, Moczulski DK, Hanna L, Scott LJ, Warram JH, Krolewski AS. APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies. Diabetes. 2000;44:2190-95.
30. Kimura H, Suzuki Y, Gejyo F, Karasawa R, Miyazaki R, Suzuki S, et al. Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am J Kidney Dis. 1998;31:666-73.
31. Eto M, Horita K, Morikawa A, Nakata H, Okada M, Saito M, et al. Increased frequency of apolipoprotein ε2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy. Clin Genet. 1995;48:288-92.
32. Liberopoulos E, Siamopoulos K, Elisaf M. Apolipoprotein E and renal disease. Am J Kidney Dis. 2004;43:223-33.
33. Tolonen N, Forsblom C, Thorn L, Wadén J, Rosengård- Bärlund M, Saraheimo M, et al. Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes. Diabetologia. 2009;52:2522-30.
34. Borges CR, Rehder DS, Jarvis JW, Schaab MR, Oran PE, Nelson RW. Full-length characterization of proteins in human populations. Clin Chem. 2010;56:202-11.